230 related articles for article (PubMed ID: 33203876)
1. Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells.
Huang D; Tran JT; Olson A; Vollbrecht T; Tenuta M; Guryleva MV; Fuller RP; Schiffner T; Abadejos JR; Couvrette L; Blane TR; Saye K; Li W; Landais E; Gonzalez-Martin A; Schief W; Murrell B; Burton DR; Nemazee D; Voss JE
Nat Commun; 2020 Nov; 11(1):5850. PubMed ID: 33203876
[TBL] [Abstract][Full Text] [Related]
2. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion.
Nahmad AD; Raviv Y; Horovitz-Fried M; Sofer I; Akriv T; Nataf D; Dotan I; Carmi Y; Burstein D; Wine Y; Benhar I; Barzel A
Nat Commun; 2020 Nov; 11(1):5851. PubMed ID: 33203857
[TBL] [Abstract][Full Text] [Related]
3. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.
Chen X; Zhou T; Schmidt SD; Duan H; Cheng C; Chuang GY; Gu Y; Louder MK; Lin BC; Shen CH; Sheng Z; Zheng MX; Doria-Rose NA; Joyce MG; Shapiro L; Tian M; Alt FW; Kwong PD; Mascola JR
Immunity; 2021 Feb; 54(2):324-339.e8. PubMed ID: 33453152
[TBL] [Abstract][Full Text] [Related]
4. Vaccination induces HIV broadly neutralizing antibody precursors in humans.
Leggat DJ; Cohen KW; Willis JR; Fulp WJ; deCamp AC; Kalyuzhniy O; Cottrell CA; Menis S; Finak G; Ballweber-Fleming L; Srikanth A; Plyler JR; Schiffner T; Liguori A; Rahaman F; Lombardo A; Philiponis V; Whaley RE; Seese A; Brand J; Ruppel AM; Hoyland W; Yates NL; Williams LD; Greene K; Gao H; Mahoney CR; Corcoran MM; Cagigi A; Taylor A; Brown DM; Ambrozak DR; Sincomb T; Hu X; Tingle R; Georgeson E; Eskandarzadeh S; Alavi N; Lu D; Mullen TM; Kubitz M; Groschel B; Maenza J; Kolokythas O; Khati N; Bethony J; Crotty S; Roederer M; Karlsson Hedestam GB; Tomaras GD; Montefiori D; Diemert D; Koup RA; Laufer DS; McElrath MJ; McDermott AB; Schief WR
Science; 2022 Dec; 378(6623):eadd6502. PubMed ID: 36454825
[TBL] [Abstract][Full Text] [Related]
5. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
6. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.
Xie Z; Lin YC; Steichen JM; Ozorowski G; Kratochvil S; Ray R; Torres JL; Liguori A; Kalyuzhniy O; Wang X; Warner JE; Weldon SR; Dale GA; Kirsch KH; Nair U; Baboo S; Georgeson E; Adachi Y; Kubitz M; Jackson AM; Richey ST; Volk RM; Lee JH; Diedrich JK; Prum T; Falcone S; Himansu S; Carfi A; Yates JR; Paulson JC; Sok D; Ward AB; Schief WR; Batista FD
Science; 2024 May; 384(6697):eadk0582. PubMed ID: 38753770
[TBL] [Abstract][Full Text] [Related]
7. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Alt FW; Tian M
Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
[TBL] [Abstract][Full Text] [Related]
8. Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5.
Finney J; Yang G; Kuraoka M; Song S; Nojima T; Verkoczy L; Kitamura D; Haynes BF; Kelsoe G
J Immunol; 2019 Dec; 203(12):3268-3281. PubMed ID: 31732530
[TBL] [Abstract][Full Text] [Related]
9. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.
Williams WB; Wiehe K; Saunders KO; Haynes BF
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332
[TBL] [Abstract][Full Text] [Related]
10. Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection.
Muenchhoff M; Chung AW; Roider J; Dugast AS; Richardson S; Kløverpris H; Leslie A; Ndung'u T; Moore P; Alter G; Goulder PJR
mSphere; 2020 Dec; 5(6):. PubMed ID: 33361123
[TBL] [Abstract][Full Text] [Related]
11. HIV Broadly Neutralizing Antibodies: VRC01 and Beyond.
Wu X
Adv Exp Med Biol; 2018; 1075():53-72. PubMed ID: 30030789
[TBL] [Abstract][Full Text] [Related]
12. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.
Sacks D; Wiehe K; Morris L; Moore PL
J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865
[TBL] [Abstract][Full Text] [Related]
13. Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models.
Tian M; McGovern K; Cheng HL; Waddicor P; Rieble L; Dao M; Chen Y; Kimble MT; Cantor E; Manfredonia N; Judson R; Chapdelaine-Williams A; Cain DW; Haynes BF; Alt FW
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):7929-7940. PubMed ID: 32209668
[TBL] [Abstract][Full Text] [Related]
14. Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth.
Roskin KM; Jackson KJL; Lee JY; Hoh RA; Joshi SA; Hwang KK; Bonsignori M; Pedroza-Pacheco I; Liao HX; Moody MA; Fire AZ; Borrow P; Haynes BF; Boyd SD
Nat Immunol; 2020 Feb; 21(2):199-209. PubMed ID: 31959979
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
[TBL] [Abstract][Full Text] [Related]
16. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.
Steichen JM; Lin YC; Havenar-Daughton C; Pecetta S; Ozorowski G; Willis JR; Toy L; Sok D; Liguori A; Kratochvil S; Torres JL; Kalyuzhniy O; Melzi E; Kulp DW; Raemisch S; Hu X; Bernard SM; Georgeson E; Phelps N; Adachi Y; Kubitz M; Landais E; Umotoy J; Robinson A; Briney B; Wilson IA; Burton DR; Ward AB; Crotty S; Batista FD; Schief WR
Science; 2019 Dec; 366(6470):. PubMed ID: 31672916
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
[TBL] [Abstract][Full Text] [Related]
18. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice.
Sok D; Briney B; Jardine JG; Kulp DW; Menis S; Pauthner M; Wood A; Lee EC; Le KM; Jones M; Ramos A; Kalyuzhniy O; Adachi Y; Kubitz M; MacPherson S; Bradley A; Friedrich GA; Schief WR; Burton DR
Science; 2016 Sep; 353(6307):1557-1560. PubMed ID: 27608668
[TBL] [Abstract][Full Text] [Related]
19. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
[TBL] [Abstract][Full Text] [Related]
20. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.
Verkoczy L; Chen Y; Zhang J; Bouton-Verville H; Newman A; Lockwood B; Scearce RM; Montefiori DC; Dennison SM; Xia SM; Hwang KK; Liao HX; Alam SM; Haynes BF
J Immunol; 2013 Sep; 191(5):2538-50. PubMed ID: 23918977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
